A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Clinical trial NCT05057494 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05057494
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-12
- Primary completion
- 2027-07-15
- Enrollment
- 607
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.